Relay Therapeutics
(NASDAQ) RLAY
Relay Therapeutics Financials at a Glance
Market Cap
$2.24B
Revenue (TTM)
$15.36M
Net Income (TTM)
$276.48M
EPS (TTM)
$-1.61
P/E Ratio
-7.77
Dividend
$0.00
Beta (Volatility)
1.79 (High)
Dividend
$0.00
Beta (Volatility)
1.79 (High)
Price
$12.55
Volume
225,700
Open
$10.58
Price
$12.55
Volume
225,700
Open
$10.58
Previous Close
$12.55
Daily Range
$10.58 - $13.03
52-Week Range
$1.77 - $13.04
Dividend
$0.00
Beta (Volatility)
1.79 (High)
Price
$12.55
Volume
225,700
Open
$10.58
Previous Close
$12.55
Daily Range
$10.58 - $13.03
52-Week Range
$1.77 - $13.04
RLAY News
RLAY: Motley Fool Moneyball Superscore
Our CEO Is Handing Members His Secret Weapon
It's called Motley Fool Moneyball, our new proprietary AI tool
We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.
Get Access NowAbout Relay Therapeutics
Industry
Biotechnology
Sector
Health CareEmployees
192
CEO
Sanjiv K. Patel, MD, MBA
Website
www.relaytx.comHeadquarters
Cambridge, MA 02139, US
RLAY Financials
Key Financial Metrics (TTM)
Gross Margin
91%
Operating Margin
-20%
Net Income Margin
-18%
Return on Equity
-41%
Return on Capital
-51%
Return on Assets
-44%
Earnings Yield
-12.87%
Dividend Yield
0.00%
Payout Ratio
0.00%
Stock Overview
Market Cap
$2.24B
Shares Outstanding
178.73M
Volume
225.70K
Short Interest
0.00%
Avg. Volume
2.54M
Financials (TTM)
Gross Profit
$11.80M
Operating Income
$302.74M
EBITDA
$272.92M
Operating Cash Flow
$235.46M
Capital Expenditure
$410.00K
Free Cash Flow
$235.87M
Cash & ST Invst.
$554.52M
Total Debt
$32.46M
Relay Therapeutics Performance Analysis
Revenue Growth Rate
Annual and quarterly growth comparisonEarnings Per Share Growth Rate
Annual and quarterly EPS growth comparisonQuarterly Performance
Revenue
$7.00M
N/A
Gross Profit
$6.40M
N/A
Gross Margin
91.44%
N/A
Market Cap
$2.24B
N/A
Market Cap/Employee
$8.65M
N/A
Employees
259
N/A
Net Income
$54.89M
+27.8%
EBITDA
$57.85M
+30.8%
Quarterly Fundamentals
Net Cash
$522.06M
-28.8%
Accounts Receivable
$0.00
N/A
Inventory
$0.00
N/A
Long Term Debt
$28.69M
-32.9%
Short Term Debt
$3.77M
-34.3%
Return on Assets
-44.50%
N/A
Return on Invested Capital
-50.82%
N/A
Free Cash Flow
$44.87M
+22.5%
Operating Cash Flow
$44.87M
+22.5%